Cancer drug biotech Enliven shifts to reverse to move forward as a public company

Cancer drug biotech Enliven shifts to reverse to move forward as a public company

Source: 
MedCity News
snippet: 

Enliven Therapeutics’ reverse merger with Imara will form a combined company with $300 million to finance clinical development of new cancer drugs. Its most advanced program is a tyrosine kinase inhibitor for chronic myeloid leukemia.